ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / IMA / forecast
LONA (35) TIL (39) CRBU (32) INMB (30) ⌘ Pro Terminal →

ImageneBio Inc. (IMA) 12-Month Stock Forecast & Price Target Cone

$4.09 -0.24% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.08

ImageneBio Inc. (IMA) carries a Roarable Rating of E (Strong Sell) with 19/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $46.5M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IMA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is IMA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, ImageneBio Inc. (NASDAQ: IMA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 19/100 at a spot price of $4.09 (-0.24% 1D, market cap $46.5M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, IMA ranks #994 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does IMA compare to LONA and TIL in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IMA carries a Roarable E (19/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LONA (LeonaBio Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $46.5M) and TIL (Instil Bio Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $46.1M). Among the 5-stock peer group, IMA leads on earnings multiple (N/A) while IMA leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IMA?
▼

Per IMA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001835579), ImageneBio Inc. generated $800.0K in revenue (-77.1% YoY), -$45.3M in net income, and -$47.8M in free cash flow against $153.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $4.08 (-0.23%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (19/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-12.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510019
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E
Cash (3)Whales (3)SEC (5)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-17.6% Base Target
$9 Bull$3 Base$3 Bear
📬 FREE IMA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IMA)Realized 20D OHLCV Swing Band: ±11.5%
Deterministic 5-Pillar Attribution (19/100 Composite)
🔍 WHY IMA SCORES 19/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+7/20 pts (37% of score)

FRED Regime × Technicals: 4% of 52W Range • RSI-14 at 41.2 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+5/20 pts (26% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 1/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
27
Grade E$4.24-2.6% Next Q
Q2 (-2Q)
24
Grade E$4.13-2.7% Next Q
Q3 (-1Q)
22
Grade E$4.02+1.7% Next Q
Current
19
Grade E$4.09-12% Hist 90D α
Trajectory: E (27) → E (19)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a IMA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While IMA currently carries a cautious 19/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.61) and Max Pain ($4.29) forces dealer call-delta covering toward $9.28.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IMA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IMA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 19%NO 81%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your IMA Position Size: $10,000

Shares at $4.09: 2445.0 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $2.63
$6,430
$-3,570 (-35.7%)
12M Consensus BaseTarget $3.37
$8,240
$-1,760 (-17.6%)
12M Bull Case BreakoutTarget $9.28
$22,689
+$12,689 (+126.9%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$474%A
Goldman SachsSector Coverage LeadUNDERPERFORM$969%B
JP MorganUS Large-Cap ResearchSELL$358%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IMA)

  • ✓Walkthrough of IMA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
IMA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -28.50%▼ DESCENDING CHANNEL
2026-11-03O $4.05H $4.10L $4.05C $4.09VOL 5.7K
RES: $6.02SUP: $3.49SMA50: $4.61SMA200: $5.61
$8.57$7.30$6.03$4.76$3.49RES $6.02SUP $3.49$4.092026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IMA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IMA Butterfly Map → + Track IMA →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -77.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on IMA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IMA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IMA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IMA)

Health Care Rank #994 of 1015 ⚔️ LONA vs IMA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IMA vs. LONA, TIL, CRBU, INMB)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, ImageneBio Inc. (IMA) ranks #994 by composite RQD confidence (19/100, grade E) and #754 by equity capitalization ($46.5M). Within this direct 5-issuer industry benchmark cohort, IMA leads on earnings valuation at N/A trailing P/E, while IMA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. TIL currently holds the highest overall quantitative score in the immediate peer group at 39/100 (D-) compared with IMA at 19/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
IMA ACTIVE
ImageneBio Inc.
E 19/100 — — -35.0% -0.24% $46.5M Benchmark Subject
LONA
LeonaBio Inc.
D- 35/100 — — -35.0% -4.25% $46.5M /lona-vs-ima →
TIL
Instil Bio Inc.
D- 39/100 — — -35.0% -3.68% $46.1M /til-vs-ima →
CRBU
Caribou Biosciences Inc.
E 32/100 — — -35.0% +3.95% $45.4M /crbu-vs-ima →
INMB
INmune Bio Inc.
E 30/100 — — -35.0% -4.83% $44.9M /inmb-vs-ima →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001835579 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), ImageneBio Inc. (IMA) reported GAAP revenue of $800.0K (-77.1% vs. FY2024 revenue of $3.5M , and -91.3% cumulative change since FY2023) , GAAP net income of -$45.3M, operating cash flow of -$47.8M, and free cash flow of -$47.8M (-124.4% YoY). On the balance sheet, IMA closed FY2025 with $153.0M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $800.0K -$45.3M -$47.8M -$47.8M $153.0M —
FY2024 (FY) 2024-12-31 $3.5M -$36.6M -$21.3M -$21.3M $15.9M —
FY2023 (FY) 2023-12-31 $9.2M -$68.2M -$79.7M -$79.7M — —

3. IMA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IMA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, ImageneBio Inc. (NASDAQ: IMA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 19/100 at a spot price of $4.09 (-0.24% 1D, market cap $46.5M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, IMA ranks #994 in composite RQD confidence.

How does IMA compare to LONA and TIL in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IMA carries a Roarable E (19/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LONA (LeonaBio Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $46.5M) and TIL (Instil Bio Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $46.1M). Among the 5-stock peer group, IMA leads on earnings multiple (N/A) while IMA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IMA?

Per IMA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001835579), ImageneBio Inc. generated $800.0K in revenue (-77.1% YoY), -$45.3M in net income, and -$47.8M in free cash flow against $153.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IMA trading relative to its 50-day, 200-day, and 52-week technical levels?

IMA last traded at $4.09 (-0.24% on volume of 7,609 shares), positioning the stock -11.28% below its 50-day simple moving average ($4.61) and -27.09% below its 200-day simple moving average ($5.61). Across its 52-week range of $3.88 to $8.84, IMA sits at the 4.2% percentile with a 14-day RSI of 41.2 (NEUTRAL RANGE) and an implied next-earnings move of ±11.5% ($3.62 to $4.56).

Direct Sub-Reports: IMA RQD Cockpit IMA 12M Forecast IMA Earnings & Move IMA Dividends & DRIP IMA Insiders & 13F IMA Whale Options IMA Profit Sankey IMA News & Why
ROARABLE RATING BRIEF • RQD 19/100 (E) ✓ SEC XBRL & RQD VERIFIED

IMA — ImageneBio Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

ImageneBio Inc. (IMA) earns a live Roarable RQD composite score of 19/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $4.09 (-0.24% 1D, market capitalization $46.5M).

  • Fundamental Cash Engine (3/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

ImageneBio Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Biological Products (No Diagnostic Substances) industry. The issuer's market capitalization is $0.0B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), ImageneBio Inc. (IMA) reported $800.0K in annual revenue (up from $3.5M in FY2024, -77.1% YoY) and -$45.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($9.2M revenue, -$68.2M net income) through FY2025, IMA scaled operating cash flow to -$47.8M and free cash flow to -$47.8M, backed by $153.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 19/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 3/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $3.88 – $8.84 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream suppliers, downstream customers, and sector correlations are — Second-order bottlenecks cannot be identified from the provided sources. A prospective investor should note that the absence of mapped dependencies is itself a limitation of this analysis rather than evidence of an independent business.

  • Key Question #1: Can IMA sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $800.0K and free cash flow of -$47.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is IMA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

IMA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for ImageneBio Inc. (IMA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to IMA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

IMA Bull vs. Bear Conversation Board — What's Your Call at $4.09?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IMA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on IMA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $5.04 (+22.9%)
📌 Pinned Debate

Reported cash rose to $94.5M in FY 2025, well above the $12.1M reported for FY 2024, providing a liquidity cushion against ongoing loss

The street is overcomplicating ImageneBio Inc. (IMA). Reported cash rose to $94.5M in FY 2025, well above the $12.1M reported for FY 2024, providing a liquidity cushion against ongoing losses.. With an RQD score of 19/100 (E) and Forensic Balance Sheet at 5/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $4.43.

SectorRotator 🐂 BULL

@MidwestValue Agree on the RQD 19/100 quality, though with 1.0 beta I'm scaling in with half-size at $4.10 and keeping dry powder in case we test $3.81.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $3.28 (-20.0%)
Spot @ $4.10

ROIC of -35%, FCF of -$47.8M in FY 2025, and an Altman Z-Score of 0.2 signal ongoing cash burn and elevated forensic distress risk.

ROIC of -35%, FCF of -$47.8M in FY 2025, and an Altman Z-Score of 0.2 signal ongoing cash burn and elevated forensic distress risk.. Look at the math on IMA: paying current EV/EBITDA multiples for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Biotechnology: Biological Products (No Diagnostic Substances) demand softens. I'd wait for a retest of $3.61 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%